Digital medicine

Nicox Appoints Doug Hubatsch as new Chief Scientific Officer to lead Clinical and Non-clinical Development

Retrieved on: 
Monday, December 13, 2021
Kepler, Therapy, Allergic conjunctivitis, Glaucoma, Development, Euronext Paris, Johannes Kepler, Duane syndrome, Group, AstraZeneca, Brinzolamide/brimonidine, LLC, Medical Affairs Bureau, Global Medical Device Nomenclature, NCX, Research, Intraocular pressure, Patient, Alcon, COX, Blepharitis, Compartment, Bausch & Lomb, Digital medicine, Fluticasone, Secondary research, Ophthalmology, Roche, Pharmaceutical industry, NicOx, Novartis

Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced the appointment of Doug Hubatsch to lead all of the Companys non-clinical and clinical development activities.

Key Points: 
  • Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced the appointment of Doug Hubatsch to lead all of the Companys non-clinical and clinical development activities.
  • As Chief Scientific Officer, Doug Hubatsch will be responsible for setting the research and development strategy of the Group and will be a member of the Nicox Executive Committee, reporting to Michele Garufi, Chief Executive Officer.
  • Doug will be responsible for implementing the future development strategy for all of our pipeline assets.
  • Nicoxs lead program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with glaucoma.

Castor Appoints Digital Leader Milind Kamkolkar to Board of Directors

Retrieved on: 
Tuesday, November 9, 2021
Biotechnology, Pharmaceutical, Health, Clinical Trials, Efficiency, Industry, DNA digital data storage, Novartis, Digital medicine, Leadership, World, Doctor of Philosophy, World Health Organization, Technology, Senior advisor, Clinical data management, Founder, Research, Digital, AI, Solidarity trial, Board, Twitter, Company, Therapy, Board of directors, Patient, Pharmaceutical industry, Fine chemical, Management

Castor , a leading provider of decentralized and hybrid clinical trial solutions, today announced the appointment of industry veteran Milind Kamkolkar to its Board of Directors.

Key Points: 
  • Castor , a leading provider of decentralized and hybrid clinical trial solutions, today announced the appointment of industry veteran Milind Kamkolkar to its Board of Directors.
  • Milind is currently Senior Advisor to Cellarity, a Flagship Pioneering Company, after his tenure as Chief Digital & Data Officer.
  • He brings to Castor more than 20 years of experience in healthcare AI and digital health, from startup, management consulting to Fortune 500 enterprises.
  • The adoption of decentralized clinical trials has seen exponential growth, catalyzing an industry in critical need of modernization, said Milind.

OptimizeRx Appoints Seasoned Financial and Operational Executive, Edward Stelmakh as Chief Financial Officer and Chief Operations Officer

Retrieved on: 
Thursday, September 30, 2021
Arts Council of Princeton, Securities Act of 1933, Partnership, American Foundation for Suicide Prevention, University, Solution, Regulation, Sanofi, Secretary of State of New Jersey, Patient, Mylan, Towson University, Arts council, CEO, Accounting, Acquisition, Growth, Leadership, Science, COVID-19, Technology, Johnson & Johnson, MBA, Information technology, CFO, Forward-looking statement, Organization, Securities Exchange Act of 1934, Digital medicine, COO, Data Analytics Acceleration Library, LabCorp, GLOBE, Management

He succeeds Doug Baker within the financial organization, who will continue as executive vice president of finance and accounting.

Key Points: 
  • He succeeds Doug Baker within the financial organization, who will continue as executive vice president of finance and accounting.
  • The addition of operational focus at the Companys executive level ensures that all internal organizations ultimately remain poised for scalability and growth.
  • His background includes leadership positions across a broad spectrum of financial, commercial, partnership/alliance governance, and operational roles.
  • Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.

The Power of the Platform in Psychedelic Medicine

Retrieved on: 
Tuesday, April 20, 2021
Drugs, Psychoactive drugs, Health sciences, Hallucinations, Euphoriants, Ketamine, Sedatives, Digital medicine, Medication, Psychedelic drug

OTC Stock Review introduced a large number of investors to the psychedelic sector with an article on Seeking Alpha March 6, 2020 titled " Psychedelic Medicine Stocks Capture the Attention of Investors ."

Key Points: 
  • OTC Stock Review introduced a large number of investors to the psychedelic sector with an article on Seeking Alpha March 6, 2020 titled " Psychedelic Medicine Stocks Capture the Attention of Investors ."
  • MindMed recently announced it would establish a digital medicine division known as Albert to research, develop and build an integrated technical platform and comprehensive toolset aimed at delivering psychedelic inspired medicines and experiential therapies combined with digital therapeutics.
  • It is a data driven platform that has been strategically developed to provide better communication among medical practitioners and health care providers.
  • Ehave\'s Dashboard is also a key component of its ketamine home delivery platform known as KetaDASH www.ketadash.com.

PhysIQ Announces Strategic Collaboration to Scale Digital Medicine

Retrieved on: 
Tuesday, April 20, 2021
Medical devices, Infectious diseases, Hospitals, Clinical trials, Cardiology, Other Health, Biotechnology, Pharmaceutical, Health, Oncology, Health sciences, Health, Life sciences, Biomarkers, Biosensors, Digital medicine, Janssen Pharmaceuticals, Sensor, Pharmaceutical industry in China

The relationship allows Janssen to scale the use of biosensors, supporting initiatives across both R&D and commercial strategies.

Key Points: 
  • The relationship allows Janssen to scale the use of biosensors, supporting initiatives across both R&D and commercial strategies.
  • View the full release here: https://www.businesswire.com/news/home/20210420005278/en/\nPhysIQ announces multi-year collaboration with Janssen Pharmaceuticals to scale digital medicine (Photo: Business Wire)\nContinuous data collected from wearable biosensors represents game-changing potential for biopharma clinical and commercial teams.
  • However, collecting, processing, and analyzing continuously streaming biosensor data presents technical challenges that, to date, have limited companies\xe2\x80\x99 ability to scale their digital medicine operations.
  • This collaboration reflects the rapid maturation of digital medicine and its strategic clinical implications.\n\xe2\x80\x9cContinuous real-world sensor data and digital biomarkers are the new frontier of clinical development and pharma commercialization,\xe2\x80\x9d said Chris Economos, Chief Commercial Officer of physIQ.

Blue Matter Launches Initiative Focused on Digital Health

Retrieved on: 
Tuesday, March 2, 2021
Digital medicine, Consultant, UST

NEW YORK, March 2, 2021 /PRNewswire/ -- Blue Matter, a leading strategic consulting firm focused on the life sciences industry, has launched a new initiative to help life science companies develop and commercialize digital health solutions.

Key Points: 
  • NEW YORK, March 2, 2021 /PRNewswire/ -- Blue Matter, a leading strategic consulting firm focused on the life sciences industry, has launched a new initiative to help life science companies develop and commercialize digital health solutions.
  • Digital health solutions encompass a variety of emerging products and services including digital therapeutics, digital biomarkers, digital medicine, clinical decision support tools, and adherence technologies.
  • Blue Matter has appointed Jeff Liesch, Ph.D. to lead the initiative.
  • Blue Matter ( www.bluematterconsulting.com ) is a strategic consulting firm serving the life sciences industry.From its offices in North America and Europe, Blue Matter serves pharmaceutical and biotech companies from around the globe.

WeHealth™ Digital Medicine and BioSerenity Initiate a New Phase to Accelerate Cardioskin™ Commercialization

Retrieved on: 
Tuesday, February 23, 2021
Health informatics, Health, Digital health, Digital medicine, Medicine, Health professional, Laboratoires Servier

PARIS and ATLANTA, Feb. 23, 2021 /PRNewswire/ --WeHealth Digital Medicine, Servier Group's e-health division, and BioSerenity, today announced that BioSerenity acquired the global distribution rights to CardioskinTM, the first WeHealthTMdigital solution co-developed with a start-up, to accelerate the commercialization of Cardioskin.

Key Points: 
  • PARIS and ATLANTA, Feb. 23, 2021 /PRNewswire/ --WeHealth Digital Medicine, Servier Group's e-health division, and BioSerenity, today announced that BioSerenity acquired the global distribution rights to CardioskinTM, the first WeHealthTMdigital solution co-developed with a start-up, to accelerate the commercialization of Cardioskin.
  • "In today's world, digital health care is becoming more prevalent," said Pierre-Yves Frouin, Chief Executive Officer of BioSerenity.
  • "Dr. David Guez, founder of Servier's WeHealth Digital Medicine, had the vision to develop remote Cardiology.
  • WeHealth Digital Medicine, aims to improve the daily life of patients and health professionals' alike using digital means.

Global Health Crisis Shines Light on the Future of the Telehealth Industry

Retrieved on: 
Thursday, February 18, 2021
Health sciences, Health, Pharmaceutical industry, Life sciences, Disability, Mental health, Positive psychology, Social constructionism, Medication, Digital medicine, Clinical trial

The acquisition will include HealthMode's Intellectual Property, platforms for clinical drug trials, and its entire twenty-four person digital medicine team.

Key Points: 
  • The acquisition will include HealthMode's Intellectual Property, platforms for clinical drug trials, and its entire twenty-four person digital medicine team.
  • MindMed's goal is to make Albert into an industry leading full stack digital mental health platform that is capable of launching and commercializing psychedelic-assisted therapies and medicines at scale for patients.
  • MindMed's acquisition of HealthMode will add two new members to their executive team: pharmaceutical veteran Daniel R. Karlin M.D.
  • Dan and I founded HealthMode with this goal and pursued mental health biotech opportunities throughout the past few years.

Global Health Crisis Shines Light on the Future of the Telehealth Industry

Retrieved on: 
Thursday, February 18, 2021
Health sciences, Health, Pharmaceutical industry, Life sciences, Disability, Mental health, Positive psychology, Social constructionism, Medication, Digital medicine, Clinical trial

The acquisition will include HealthMode's Intellectual Property, platforms for clinical drug trials, and its entire twenty-four person digital medicine team.

Key Points: 
  • The acquisition will include HealthMode's Intellectual Property, platforms for clinical drug trials, and its entire twenty-four person digital medicine team.
  • MindMed's goal is to make Albert into an industry leading full stack digital mental health platform that is capable of launching and commercializing psychedelic-assisted therapies and medicines at scale for patients.
  • MindMed's acquisition of HealthMode will add two new members to their executive team: pharmaceutical veteran Daniel R. Karlin M.D.
  • Dan and I founded HealthMode with this goal and pursued mental health biotech opportunities throughout the past few years.

MindMed Reaches Agreement to Acquire HealthMode, a Leading Machine Learning Digital Medicine Company

Retrieved on: 
Thursday, February 18, 2021
Medicine, Digital medicine, In silico, Health sciences, Health, Life sciences

With the acquisition, MindMed gains access to HealthMode's Intellectual Property, platforms for clinical drug trials, and its entire twenty-four person digital medicine team.

Key Points: 
  • With the acquisition, MindMed gains access to HealthMode's Intellectual Property, platforms for clinical drug trials, and its entire twenty-four person digital medicine team.
  • MindMed will incorporate HealthMode's machine learning (ML) engineering, product development, and operations employees based in Silicon Valley, New York City, Bratislava and Prague into MindMed's newly established digital medicine division, Albert.
  • MindMed Co-Founder and CEO J.R. Rahn said: "Our mission is to make MindMed as much a digital medicine company as a drug development company.
  • With the addition of Dan and Bradford's team of engineers and product experts, our digital medicine division, Albert, is now the Special Ops of digital medicine, applying machine learning to drug development and patient care.